| dc.rights.license | Green Published, Bronze | |
| dc.date.accessioned | 2021-06-03T08:21:08Z | |
| dc.date.available | 2021-06-03T08:21:08Z | |
| dc.date.issued | 2020 | |
| dc.identifier.issn | 2233-8276 | |
| dc.identifier.uri | www.doi.org/10.5415/apallergy.2020.10.e29 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12619/95311 | |
| dc.description | Bu yayın 06.11.1981 tarihli ve 17506 sayılı Resmî Gazete’de yayımlanan 2547 sayılı Yükseköğretim Kanunu’nun 4/c, 12/c, 42/c ve 42/d maddelerine dayalı 12/12/2019 tarih, 543 sayılı ve 05 numaralı Üniversite Senato Kararı ile hazırlanan Sakarya Üniversitesi Açık Bilim ve Açık Akademik Arşiv Yönergesi gereğince açık akademik arşiv sistemine açık erişim olarak yüklenmiştir. | |
| dc.description.abstract | Background: Acetylsalicylic acid/aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used drugs that may cause hypersensitivity reactions in a substantial proportion of patients. Physicians ought to be aware of these situations. Objective: We aimed to present the clinical characteristics and rates of tolerability to cyclooxygenase (COX)-2 inhibitor analgesics in patients who had admitted due to multiple cross-reactive type of NSAID hypersensitivity. Methods: The files of the patients who had admitted with multiple NSAIDs-induced symptoms were investigated retrospectively. Age, sex, underlying diseases, clinical manifestation, skin test results, and drug provocation test results were analyzed. Results: In 105 patients with multiple cross-reactive type of NSAID hypersensitivity, we found the rate of cross-reactivity to any of the relatively safe alternatives including paracetamol, meloxicam, and nimesulide to be 16.1%. The rate of cross-reactivity to these relatively safe drugs was significantly higher in patients with a history of anaphylaxis induced by NSAID intake (p= 0.006). Conclusion: The diagnosis of COX-1-mediated multiple NSAID hypersensitivity can be often established with a detailed history. Although rare, severe hypersensitivity reactions may be observed in these patients. Undesired situations for both patients and physicians may be avoided by testing relatively safe paracetamol and COX-2 inhibitors in experienced centers. | |
| dc.language | English | |
| dc.language.iso | İngilizce | |
| dc.publisher | ASIA PACIFIC ASSOC ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY | |
| dc.relation.isversionof | 10.5415/apallergy.2020.10.e29 | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | CLASSIFICATION | |
| dc.subject | ASPIRIN | |
| dc.subject | NSAIDS | |
| dc.subject | ACETAMINOPHEN | |
| dc.subject | INTOLERANCE | |
| dc.subject | MANAGEMENT | |
| dc.subject | DIAGNOSIS | |
| dc.subject | Cyclooxygenase-2 inhibitors | |
| dc.subject | Hypersensitivity | |
| dc.subject | Nonnarcotic analgesics | |
| dc.subject | Nonsteroidal anti-inflammatory agents | |
| dc.subject | Paracetamol | |
| dc.title | Tolerability to paracetamol and preferential COX-2 inhibitors in patients with cross-reactive nonsteroidal anti-inflammatory drugs hypersensitivity | |
| dc.type | Article | |
| dc.contributor.authorID | Tulumen Ozturk, Raziye/0000-0001-9503-661X | |
| dc.contributor.authorID | Ekerbicer, Hasan Cetin/0000-0003-0064-3893 | |
| dc.identifier.volume | 10 | |
| dc.relation.journal | ASIA PACIFIC ALLERGY | |
| dc.identifier.issue | 3 | |
| dc.identifier.wos | WOS:000557016600006 | |
| dc.identifier.doi | 10.5415/apallergy.2020.10.e29 | |
| dc.identifier.eissn | 2233-8268 | |
| dc.contributor.author | Terzioglu, Kadriye | |
| dc.contributor.author | Sancar, Ozgur | |
| dc.contributor.author | Ekerbicer, Hasan Cetin | |
| dc.contributor.author | Ozturk, Raziye Tulumen | |
| dc.contributor.author | Epozturk, Kursat | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.identifier.pmıd | 32789114 |